Injectable Placebo

DRUG2 trials

Conditions

COVIDCoronavirus InfectionDermatitisDermatitis, AtopicEczemaGenetic Diseases, InbornHypersensitivityHypersensitivity, Immediate

Phase 1

Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients

NCT04472585

Sohaib AshrafCoronavirus Infection, COVID, Sars-CoV2

Start: 2020-11-14End: 2021-10-30Target: 180Updated: 2021-02-17

Phase 3

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

CompletedNCT03720470

PfizerDermatitis, Dermatitis, Atopic, Eczema +7

Start: 2018-10-29End: 2020-03-06Updated: 2021-01-19

2026-05-20

Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE

American Journal of Clinical Dermatology2026-05-05

Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.

2026-04-28

Efficacy and Safety of Abrocitinib Versus Dupilumab in Patients Who Self-Identified as Having Skin of Color: A Post Hoc Analysis of JADE COMPARE

SKIN The Journal of Cutaneous Medicine2026-03-10

Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure

SKIN The Journal of Cutaneous Medicine2025-11-10

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

2025-09-23

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Dermatology and Therapy2025-02-014 citations

Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.

2024-06-19

Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure

American Journal of Clinical Dermatology2024-06-1834 citations

Abrocitinib May Improve Itch and Quality of Life in Patients with Itch-Dominant Atopic Dermatitis

Skin Health and Disease2024-05-052 citations

Efficacy of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis With Severe Itch at Baseline and in Subgroups by Baseline Thresholds of Severe Itch: A Post Hoc Analysis of the JADE COMPARE and JADE DARE Clinical Trials

SKIN The Journal of Cutaneous Medicine2024-03-18

530 - Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study

British Journal of Dermatology2024-02-01

Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

Dermatology2023-12-118 citations

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.

2023-07-233 citations

Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis

JEADV Clinical Practice2023-06-231 citations

Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study

Journal of the European Academy of Dermatology and Venereology2023-06-1932 citations

Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension <scp>JADE EXTEND</scp> study

Journal of the European Academy of Dermatology and Venereology2023-06-156 citations

P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND

British Journal of Dermatology2023-06-012 citations

423 Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial

British Journal of Dermatology2023-06-01

424 Effect of abrocitinib vs. dupilumab on skin pain: an analysis of the phase 3 JADE COMPARE and JADE DARE trials

British Journal of Dermatology2023-06-01

14 more papers not shown

Injectable Placebo

Sponsors

Conditions

Phase 1

Phase 3

Related Papers